{
    "Trade/Device Name(s)": [
        "Dimension\u00ae NT-proBNP (PBNP) Flex\u00ae reagent cartridge method",
        "Dimension\u00ae PBNP reagent cartridge"
    ],
    "Submitter Information": "Dade Behring Inc.",
    "510(k) Number": "K071767",
    "Predicate Device Reference 510(k) Number(s)": [
        "K041417",
        "K042347"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "August 24, 2007",
    "Summary Letter Received Date": "June 29, 2007",
    "Submission Date": "June 28, 2007",
    "Regulation Number(s)": [
        "21CFR862.1117"
    ],
    "Regulation Name(s)": [
        "B-Type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "cardiac",
        "toxicology"
    ],
    "Analyte(s)": [
        "N-terminal pro-brain natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dimension\u00ae clinical chemistry system with heterogeneous immunoassay module"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay",
        "Sandwich immunoassay",
        "Chemiluminescent immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Dade Behring Dimension NT-proBNP (PBNP) Flex reagent cartridge method for quantification of NT-proBNP in human serum or plasma.",
    "Indications for Use Summary": "Quantitative determination of NT-proBNP in human serum or plasma as an aid in diagnosis and severity assessment of congestive heart failure, and for risk stratification of patients with acute coronary syndrome and heart failure.",
    "fda_folder": "Clinical Chemistry"
}